Related references
Note: Only part of the references are listed.Combined Gene Expression and Genomic Profiling Define Two Intrinsic Molecular Subtypes of Urothelial Carcinoma and Gene Signatures for Molecular Grading and Outcome
David Lindgren et al.
CANCER RESEARCH (2010)
Genetic polymorphisms in 85 DNA repair genes and bladder cancer risk
Stefan Michiels et al.
CARCINOGENESIS (2009)
Consistent genomic alterations in carcinoma in situ of the urinary bladder confirm the presence of two major pathways in bladder cancer development
Karsten Zieger et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
p19Arf inhibits the invasion of hepatocellular carcinoma cells by binding to C-terminal binding protein
Ya-Wen Chen et al.
CANCER RESEARCH (2008)
Inactivation of the Rb pathway and overexpression of both isoforms of E2F3 are obligate events in bladder tumours with 6p22 amplification
C. D. Hurst et al.
ONCOGENE (2008)
Molecular pathways in invasive bladder cancer: New insights into mechanisms, progression, and target identification
Anirban P. Mitra et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Chromosome 9 deletions are more frequent than FGFR3 mutations in flat urothelial hyperplasias of the bladder
Johanna M. M. van Oers et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials
RJ Sylvester et al.
EUROPEAN UROLOGY (2006)
Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?
MA Knowles
CARCINOGENESIS (2006)
A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine
JMM van Oers et al.
CLINICAL CANCER RESEARCH (2005)
Comprehensive analysis of CDKN2A status in microdissected urothelial cell carcinoma reveals potential haploinsufficiency, a high frequency of homozygous co-deletion and associations with clinical phenotype
EJ Chapman et al.
CLINICAL CANCER RESEARCH (2005)
Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background
J Ackermann et al.
CANCER RESEARCH (2005)
Cell type-specific tumor suppression by Ink4a and Arf in kras-induced mouse gliomagenesis
L Uhrbom et al.
CANCER RESEARCH (2005)
Urothelial tumorigenesis: A tale of divergent pathways
XR Wu
NATURE REVIEWS CANCER (2005)
Measurement of relative copy number of CDKN2A/ARF and CDKN2B in bladder cancer by real-time quantitative PCR and multiplex ligation-dependent probe amplification
JS Aveyard et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2004)
Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma
AJ Aguirre et al.
GENES & DEVELOPMENT (2003)
Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders
BWG van Rhijn et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2002)
Synergism between INK4a/ARF inactivation and aberrant HGF/SF signaling in rhabdomyosarcomagenesis
R Sharp et al.
NATURE MEDICINE (2002)
Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes
GH Fisher et al.
GENES & DEVELOPMENT (2001)
The INK4a/ARF network in tumour suppression
CJ Sherr
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2001)
Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors
C Billerey et al.
AMERICAN JOURNAL OF PATHOLOGY (2001)
DNA methylation and the mechanisms of CDKN2A inactivation in transitional cell carcinoma of the urinary bladder
AR Florl et al.
LABORATORY INVESTIGATION (2000)
Share Paper
